Bert Schepens

Ghent University — Belgium

Medicine · Health Sciences

38h-index4.8kcitations87works2.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Influenza Virus Research Studies(34), Monoclonal and Polyclonal Antibodies Research(28), Respiratory viral infections research(26), Viral gastroenteritis research and epidemiology(13), SARS-CoV-2 and COVID-19 Research(12)

Publications87 total

Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base
Nature Communications·2025· 8 citedOpen Access
Modeling epithelial and endothelial cell tropism for SARS-CoV-2 through restricted transgenic hACE2 expression in mice
2025Open Access
Development of a General Purpose Targeted LC-MS Method for Accurate Quantification of the SARS-CoV-2 Spike Protein Expression
2025Open Access
P-2023. A ‘Variant-Proof’ Cocktail Of Two Heavy Chain-Only Antibodies Targets 3 Epitopes In The Spike Protein S1 And S2 Subunits And Broadly Neutralizes SARS-Cov-2 With Exceptional Potency
Open Forum Infectious Diseases·2025Open Access
Yeast-based production platform for potent and stable heavy chain-only antibodies
2024Open Access
Integrating artificial intelligence-based epitope prediction in a SARS-CoV-2 antibody discovery pipeline: caution is warranted
EBioMedicine·2024· 7 citedOpen Access
GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery
mAbs·2023· 8 citedOpen Access
Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike
2023· 6 citedOpen Access
An Unexpected Encounter: Respiratory Syncytial Virus Nonstructural Protein 1 Interacts with Mediator Subunit MED25
Journal of Virology·2022· 17 citedOpen Access
GlycoVHH: Introducing N-glycans on the camelid VHH antibody scaffold - Optimal sites and use for macrophage delivery
2022· 2 citedOpen Access
Reduced protection of RIPK3-deficient mice against influenza by matrix protein 2 ectodomain targeted active and passive vaccination strategies
Cell Death and Disease·2022· 3 citedOpen Access
How RSV Proteins Join Forces to Overcome the Host Innate Immune Response
Viruses·2022· 43 citedOpen Access
An affinity-enhanced, broadly neutralizing heavy chain–only antibody protects against SARS-CoV-2 infection in animal models
Science Translational Medicine·2021· 66 citedOpen Access
<i>In Vivo</i> Therapy with M2e-Specific IgG Selects for an Influenza A Virus Mutant with Delayed Matrix Protein 2 Expression
mBio·2021· 7 citedOpen Access
A Vulnerable, Membrane-Proximal Site in Human Respiratory Syncytial Virus F Revealed by a Prefusion-Specific Single-Domain Antibody
Journal of Virology·2021· 17 citedOpen Access
Drug development of an affinity enhanced, broadly neutralizing heavy chain-only antibody that restricts SARS-CoV-2 in rodents
2021· 8 citedOpen Access
Single-domain antibodies make a difference
Science·2021· 21 cited
STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters
Nature Communications·2020· 287 citedOpen Access
Evaluation of the protective potential of antibody and T cell responses elicited by a novel preventative vaccine towards respiratory syncytial virus small hydrophobic protein
Human Vaccines & Immunotherapeutics·2020· 11 citedOpen Access
Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
Cell·2020· 160 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Xavier Saelens(46), Kenny Roose(17), Walter Fiers(12), Dorien De Vlieger(10), Nico Callewaert(9), Michael Schotsaert(8), Koen Sedeyn(8), Iebe Rossey(7), Lorena Itatí Ibañez(7), Sarah De Baets(7), Jason S. McLellan(6), Lien Van Hoecke(6), Daniel Wrapp(5), Barney S. Graham(5), Wander Van Breedam(4), José A. Melero(4), Peter Vanlandschoot(4), Anouk Smet(4), Kizzmekia S. Corbett(3), Gretel M. Torres(3)